Director, Center of Anti-infective Research and Development (CAIRD), Hartford Hospital CSO/Founder of Triari Pharmaceuticals, Inc.
Hartford, CT
Joined December 2011
- Tweets2.9K
- Following1.1K
- Followers776
- Likes8.2K
Daniel V. Zurawski retweeted
Yes! @manon_janet preprint is out! We show using BALF transfer that an intracelular Acinetobacter clinical strain can seed an infection in a susceptible mouse, suggesting that intracellular bacteria may be reservoir for recurrent infections 1/2
nam10.safelinks.protection.o…
Daniel V. Zurawski retweeted
The Bacterial Virulence study section that was scheduled for today was cancelled…today! We just got the communication this morning. This is disheartening…
Daniel V. Zurawski retweeted
Nobody seems to care about science, until they get cancer, infections, alzheimer, depression or any other disease. If you support Trump’s decision of stopping science (yes it is happening), next time you get sick just don’t get treatmen, prey to your God for a prompt recovery
Daniel V. Zurawski retweeted
Check out this great opportunity at @USouthFlorida !!
We are looking for a microbiologist and/or immunologist to join us at The University of South Florida in beautiful Tampa! This is an open rank position and we welcome all candidates with a passion for science and teaching to apply! jobs.sciencecareers.org/job/…
Daniel V. Zurawski retweeted
3 daily rants in one week? A new record!
It's a fair question. And the answer is, no. Even in immune suppressed patients there is no evidence that cidal vs. static means anything. Why?
Daniel V. Zurawski retweeted
We're going after the root cause of Parkinson's.
time.com/6883054/parkinsons-…
Daniel V. Zurawski retweeted
Icosahedral head of a novel bacteriophage known to hunt and kill A. Baumannii. In collaboration with @EllinorAlseth from @GeorgiaTech.
Daniel V. Zurawski retweeted
From resistance to resilience: What could the future antibiotic pipeline look like?
New @IFPMA report available: ifpma.org/publications/from-…
Daniel V. Zurawski retweeted
According to @IHME_UW, 28% of the global burden of disease is due to infections and 14% to bacterial infections. New #antibiotics are urgently needed to combat these infections! amr.solutions/2024/04/29/ram…
Daniel V. Zurawski retweeted
Called last night at 1am about an almost pan-resistant organism.
First time in ages since I've needed to remote in and review all the microbiology at night to formulate a plan.
I wonder if the rest of healthcare appreciates how common these organisms are becoming and the
Daniel V. Zurawski retweeted
It is wild to me that after fifteen years in this field you go to talks and meetings and the standard is still "let's just find another antibiotic and hope it lasts longer until evolution mysteriously overcomes it" with no sense that it might be an understandable process
Daniel V. Zurawski retweeted
New work in @SciReports measured how #antibiotics cause translation errors in bacteria🧬
Bactericidal amikacin induced stop-codon readthrough
Bacteriostatic azithromycin induced frameshifting and stop-codon readthrough💊
nature.com/articles/s41598-0…
Daniel V. Zurawski retweeted
Under the agreement, @uf scientists will conduct preclinical studies exploring effects of vaccines for neurodegenerative diseases. See more: buff.ly/42zQokj
#parkinsons #parkinsonsdisease #parkinsonsresearch #parkinsonstreatment
Daniel V. Zurawski retweeted
The nightmare has started! We have to stop hypervirulent K pneumoniae!! cidrap.umn.edu/antimicrobial…
Daniel V. Zurawski retweeted
We are excited to commence our pivotal Phase 3 clinical study of Ovaprene, a unique investigational hormone-free monthly intravaginal contraceptive. If FDA-approved, Ovaprene could be the first monthly non-hormonal contraceptive product for women: bit.ly/47GRyMC
